Several other analysts have also commented on the stock. Cantor Fitzgerald restated a buy rating and set a $53.00 price target on shares of Pfizer in a research report on Wednesday. Zacks Investment Research lowered shares of Pfizer from a buy rating to a hold rating in a research report on Tuesday. Credit Suisse Group set a $40.00 price target on shares of Pfizer and gave the company a hold rating in a research report on Sunday, October 14th. ValuEngine upgraded shares of Pfizer from a hold rating to a buy rating in a research report on Tuesday, October 9th. Finally, Morningstar set a $46.00 price target on shares of Pfizer and gave the company a neutral rating in a research report on Tuesday, October 9th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $42.80.
PFE stock traded up $0.50 during midday trading on Friday, hitting $44.50. 18,236,118 shares of the stock traded hands, compared to its average volume of 21,913,520. The firm has a market cap of $261.93 billion, a PE ratio of 16.79, a P/E/G ratio of 2.25 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer has a 1-year low of $33.20 and a 1-year high of $45.81.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be given a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.06%. Pfizer’s dividend payout ratio (DPR) is 51.32%.
In other news, insider Alexander R. Mackenzie sold 25,642 shares of the firm’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $39.51, for a total value of $1,013,115.42. Following the transaction, the insider now directly owns 127,954 shares of the company’s stock, valued at $5,055,462.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Frank A. Damelio sold 150,484 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $40.00, for a total transaction of $6,019,360.00. Following the completion of the transaction, the insider now directly owns 337,391 shares in the company, valued at $13,495,640. The disclosure for this sale can be found here. In the last quarter, insiders sold 234,096 shares of company stock worth $9,366,617. Company insiders own 0.06% of the company’s stock.
Several large investors have recently bought and sold shares of PFE. Ballew Advisors Inc purchased a new position in Pfizer during the first quarter worth about $102,000. Fort L.P. purchased a new position in Pfizer during the second quarter worth about $121,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in Pfizer during the first quarter worth about $132,000. Bray Capital Advisors purchased a new position in Pfizer during the first quarter worth about $139,000. Finally, Braun Bostich & Associates Inc. purchased a new position in Pfizer during the first quarter worth about $139,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: The risks of owning bonds
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.